Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

DOI: https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

Blood (2022) 140 (Supplement 1): 777–778.

DOI: https://doi.org/10.1182/blood-2022-163454

Published: 2022

Journal Articles

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Erik Van Dijk, Jurriaan Janssen, Matias Mendeville, G. Tjitske Los-De Vries, Margaretha GM Roemer, Phylicia Stathi, Julia Richter, Yong Soo Kim, Wolfram Klapper, Ulrich Dührsen, Andreas Hüttmann, P. J Lugtenburg, Josée M. Zijlstra, Marie Jose Kersten, Daphne de Jong, Martine E.D. Chamuleau, Bauke Ylstra

Blood (2022) 140 (Supplement 1): 9261–9263.

DOI: https://doi.org/10.1182/blood-2022-160052

Published: 2022

Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Blood (2022) 140 (Supplement 1): 2283–2285.

DOI: https://doi.org/10.1182/blood-2022-156085

Published: 2022

Journal Articles

Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

Blood (2022) 140 (Supplement 1): 369–371.

DOI: https://doi.org/10.1182/blood-2022-163244

Published: 2022

Journal Articles

Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study

Anna Sureda, Antonio Pinto, Herve Ghesquieres, Franck Morschhauser, Olivier Tournilhac, Pim Mutseaers, Josée M. Zijlstra, Floris A. De Jong, Tomas Janik, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 3696–3697.

DOI: https://doi.org/10.1182/blood-2022-162231

Published: 2022

Journal Articles

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

A.Vera de Jonge, Carolien Duetz, Wassilis S.C. Bruins, Erik D. van Werkhoven, Marcel Nijland, Marjolein W.M. Van Der Poel, Koen de Heer, Clara P.W. Klerk, Yorick Sandberg, Rob Fijnheer, Pim Mutseaers, Djamila E. Issa, Lara H. Böhmer, Roel J.W. Van Kampen, Otto J. Visser, Daphne de Jong, Josée M. Zijlstra, Tuna Mutis, Martine E.D. Chamuleau

Blood (2022) 140 (Supplement 1): 9298–9299.

DOI: https://doi.org/10.1182/blood-2022-163068

Published: 2022

Journal Articles

Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3523–3524.

DOI: https://doi.org/10.1182/blood-2022-165494

Published: 2022

Journal Articles

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Julia Driessen, Wouter J. Plattel, Lydia Visser, Anke Van Den Berg, Josée M. Zijlstra, Sanne Tonino, Gerben JC Zwezerijnen, Ronald Boellaard, Marie José Kersten, Arjan Diepstra

Blood (2022) 140 (Supplement 1): 9213–9215.

DOI: https://doi.org/10.1182/blood-2022-166120

Published: 2022

Journal Articles

High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

A. Vera de Jonge, Erik D. van Werkhoven, Marcel Nijland, Koen de Heer, Marjolein W.M. Van Der Poel, Yorick Sandberg, Clara Klerk, Esther E.E. Drees, Margaretha GM Roemer, Daphne de Jong, D. Michiel Pegtel, Bronno van der Holt, Tuna Mutis, Josée M Zijlstra, Marie José Kersten, Martine E.D Chamuleau

Blood (2021) 138 (Supplement 1): 1414.

DOI: https://doi.org/10.1182/blood-2021-146812

Published: 2021

Journal Articles

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Thomas Pabst, Richard Greil, Dennis A. Eichenauer, Max Topp, Marianne Just, Bernd Hertenstein, Valdete Schaub, Martin Vogelhuber, Josée M Zijlstra, Annette Plütschow, Christian Baues, Andreas Rosenwald, Markus Dietlein, Peter Borchmann, Andreas Engert

Blood (2021) 138 (Supplement 1): 2438.

DOI: https://doi.org/10.1182/blood-2021-152260

Published: 2021

Journal Articles

Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma

Jakoba J Eertink, Gerben J.C Zwezerijnen, Sanne E Wiegers, Martine E.D Chamuleau, Pieternella Lugtenburg, Daphne De Jong, Bauke Ylstra, Matias Mendeville, Ulrich Dührsen, Andreas Hüttmann, Christine Schmitz, Julia Richter, Wolfram Klapper, Otto S Hoekstra, Henrica C.W de Vet, Ronald Boellaard, Josée M Zijlstra

Blood (2021) 138 (Supplement 1): 451.

DOI: https://doi.org/10.1182/blood-2021-145855

Published: 2021

Journal Articles

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

Julia Driessen, Fer de Wit, Alex F. Herrera, Pier Luigi Luigi Zinzani, Ann S. LaCasce, Craig H. Moskowitz, Ramon Garcia-Sanz, Peter D. Cole, Michael Fuchs, Horst Mueller, Peter Borchmann, Heiko Schöder, Josée M Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten

Blood (2021) 138 (Supplement 1): 879.

DOI: https://doi.org/10.1182/blood-2021-147810

Published: 2021

Journal Articles

Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Michael W. Schuster, MD, Miguel A Canales, MD PhD, Jason Westin, MD, Josée M Zijlstra, MD PhD, George A Follows, MD PhD, Reem Karmali, MDMSc, Nagesh Kalakonda, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Joost Vermaat, MD PhD, Eric Van Den Neste, MD, Sylvain Choquet, MD, Catherine Thieblemont, MD PhD, Federica Cavallo, MD PhD, Maria de Fatima De La Cruz, MD, Brian T. Hill, MD, Herve Tilly, MD PhD, Shireen Kassam, MBBS, FRCPath, PhD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Ronit Gurion, MD, Paolo Caimi, MD, Peter Martin, FRCPC, MD MS, Andrew Davies, MD PhD, Sonali M. Smith, MD, Graham P. Collins, MD DPhil, Fritz C. Offner, MD PhD, Gilles Salles, MD PhD, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita A. Joshi, Kamal Chamoun, MD, Hongwei Wang, MD PhD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Marie Maerevoet, MD

Blood (2020) 136 (Supplement 1): 34–35.

DOI: https://doi.org/10.1182/blood-2020-137025

Published: 2020

Journal Articles

18 f-FDG PET/CT Baseline Rdiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients

Jakoba J Eertink, MSc, Tim van de Brug, PhD, Sanne E Wiegers, MSc, Gerben J.C. Zwezerijnen, MD, Elisabeth Pfaehler, MSc, Pieternella J. Lugtenburg, MD PhD, Bronno van der Holt, PhD, Henrica C.W. de Vet, PhD, Otto S Hoekstra, MD PhD, Ronald Boellaard, PhD, Josée M Zijlstra, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

DOI: https://doi.org/10.1182/blood-2020-140245

Published: 2020

Journal Articles

Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study

Blood (2020) 136 (Supplement 1): 5–6.

DOI: https://doi.org/10.1182/blood-2020-137020

Published: 2020

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Paul J Bröckelmann, MD, Annette Plütschow, Richard Greil, MD, Josée M Zijlstra, MD PhD, Timothy Illidge, MD PhD, Alexander Fosså, MD PhD, Julia Meissner, MD, Andreas Zimmermann, MD, Stephan Mathas, MD, Felicitas Thol, MD, Michael Fuchs, MD, Andreas Engert, MD, Christian Baues, MD

Blood (2019) 134 (Supplement_1): 1547.

DOI: https://doi.org/10.1182/blood-2019-124351

Published: 2019

Journal Articles

Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

Blood (2019) 134 (Supplement_1): 5333.

DOI: https://doi.org/10.1182/blood-2019-122900

Published: 2019

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

DOI: https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Julia Driessen, BSc, Gerben J.C. Zwezerijnen, MD, Jakoba J Eertink, MSc, Marie José Kersten, MD PhD, Anton Hagenbeek, MD PhD, Otto S Hoekstra, MD PhD, Josée M Zijlstra, MD PhD, Ronald Boellaard, MSc, PhD

Blood (2019) 134 (Supplement_1): 4049.

DOI: https://doi.org/10.1182/blood-2019-125495

Published: 2019

NARROW

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

18 f-FDG PET/CT Baseline Rdiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients

Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only